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Summary
Background Regional monitoring of the proportion of the population who have been infected by SARS-CoV-2 is 
important to guide local management of the epidemic, but is difficult in the absence of regular nationwide serosurveys. 
We aimed to estimate in near real time the proportion of adults who have been infected by SARS-CoV-2.
Methods In this modelling study, we developed a method to reconstruct the proportion of adults who have been infected 
by SARS-CoV-2 and the proportion of infections being detected, using the joint analysis of age-stratified seroprevalence, 
hospitalisation, and case data, with deconvolution methods. We developed our method on a dataset consisting of 
seroprevalence estimates from 9782 participants (aged ≥20 years) in the two worst affected regions of France in 
May, 2020, and applied our approach to the 13 French metropolitan regions over the period March, 2020, to January, 2021. 
We validated our method externally using data from a national seroprevalence study done between May and June, 2020.
Findings We estimate that 5·7% (95% CI 5·1–6·4) of adults in metropolitan France had been infected with SARS-CoV-2 
by May 11, 2020. This proportion remained stable until August, 2020, and increased to 14·9% (13·2–16·9) by 
Jan 15, 2021. With 26·5% (23·4–29·8) of adult residents having been infected in Île-de-France (Paris region) compared 
with 5·1% (4·5–5·8) in Brittany by January, 2021, regional variations remained large (coefficient of variation [CV] 0·50) 
although less so than in May, 2020 (CV 0·74). The proportion infected was twice as high (20·4%, 15·6–26·3) 
in 20–49-year-olds than in individuals aged 50 years or older (9·7%, 6·9–14·1). 40·2% (34·3–46·3) of infections in 
adults were detected in June to August, 2020, compared with 49·3% (42·9–55·9) in November, 2020, to January, 2021. 
Our regional estimates of seroprevalence were strongly correlated with the external validation dataset (coefficient of 
correlation 0·89).
Interpretation Our simple approach to estimate the proportion of adults that have been infected with SARS-CoV-2 can 
help to characterise the burden of SARS-CoV-2 infection, epidemic dynamics, and the performance of surveillance in 
different regions.
Funding EU RECOVER, Agence Nationale de la Recherche, Fondation pour la Recherche Médicale, Institut National 
de la Santé et de la Recherche Médicale (Inserm).
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Little more than a year after the emergence of SARS-CoV-2 
and a first pandemic wave that has had devastating 
consequences across the world, most European countries 
are now being confronted with an intense second or third 
wave of SARS-CoV-2. In this context, up-to-date regional 
estimates of the proportion of the population that has 
been infected with SARS-CoV-2 and might thus be 
temporarily protected against reinfection1,2 constitute 
impor tant information. Such estimates could help to char-
acterise the burden of infection, epidemic dynamics, and 
the performance of surveillance in different regions of a 
country and inform local management of the scale of 
the epidemic. This information will become ever more 
important as the epidemic progresses and spatial hetero-
geneities in population immunity potentially increase.
In many European countries, serological studies have 
provided estimates of the proportion of the population 
infected during the first pandemic wave. For example, it 
was estimated that about 4–5% of the population in 
metropolitan France had developed antibodies against 
SARS-CoV-2 by May, 2020, with seroprevalences of the 
order of 10% in Grand Est and Île-de-France, the two 
most affected regions.3–5 Since then, the virus has con-
tinued to circulate. Unfortunately, up-to-date estimates 
of sero prevalence able to capture the most recent 
regional evolution of the epidemic are unavailable. This 
largely stems from the difficulty and cost of imple-
menting large-scale nationwide representative sero-
surveys at regular intervals.6,7 It is therefore important to 
develop methods that can track the proportion of the 
population that has been infected in different regions 
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using the joint analysis of existing seroprevalence 
data and other surveillance data that are more readily 
available in real time. Such monitoring is difficult to 
perform from the analysis of case data, since testing 
practices have changed over both time and space. Joint 
analysis of serological and death data across different 
countries has been used to reconstruct the proportion of 
infected individuals and has allowed extrapolation to 
countries where serology was not available.8,9 However, 
such an approach might have difficulties in capturing 
spread in younger age groups given low infection–
fatality ratios in these groups, and might provide lagged 
estimates given the relatively long delays between 
infection and death.
Here, we present a method to reconstruct the pro-
portion of the adult population infected by SARS-CoV-2 
and the proportion of infections detected by surveillance 
from the joint analysis of age-stratified seroprevalence, 
hospitalisation, and case data. The method is applied to 
metropolitan France and makes it possible to track in 
near real time the underlying SARS-CoV-2 infections by 
region and age group.
Methods
Infection–hospitalisation ratios
Estimates of age-stratified infection–hospitalisation ratios 
(IHRs; ie, the proportion of infected individuals in an age 
group that require hospital admission for COVID-19) 
were derived from the joint analysis of hospital isation 
and serological data documenting the impact of the first 
pandemic wave in Île-de-France and Grand Est, the 
two regions of metropolitan France that were most 
affected. This calculation has been described elsewhere.10 
In short, seroprevalence estimates were obtained from 
the SAPRIS study,4 which gathered data from the large 
population-based French cohorts Constances, E3N-E4N, 
and NutriNet-Santé, and the numbers of hospital admis-
sions were obtained from the SI-VIC database, the 
national exhaustive inpatient surveillance system used 
during the pandemic (appendix p 1). 9782 adult partici-
pants (aged ≥20 years) were recruited in the SAPRIS 
study in Île-de-France and Grand Est and sampling 
weights were used to adjust for selection and participation 
in the cohorts before random selection. Sociodemographic 
covariates were used to correct for selection and partici-
pation bias. A complete description of the SAPRIS study 
has been provided elsewhere.4
The median date of sample collection in the SAPRIS 
serosurvey was May 14, 2020 (IQR May 12 to May 19). 
Seropositive individuals were assumed to have been 
infected at least 19 days before that date (April 25). 
Assuming a delay of 11 days between infection and hos-
pital admission,11,12 these individuals would corre spond to 
hospitalisations occurring up to May 6, 2020. The IHR was 
therefore obtained by dividing the cumulative numbers of 
hospital admissions up to May 6, 2020, by the number 
of infected people estimated from the SAPRIS serosurvey. 
Seroprevalence status of the participants was inferred 
using a series of tests (ELISA-S, ELISA-NP, and sero-
neutralisation). Participants were classified as being 
truly infected, truly negative, or as having inconsistent 
serological results. The serological status of those remain-
ing participants was inferred using a multiple imputation 
method, details of which are given in the appendix (pp 2–3) 
and elsewhere.4 To adjust for the imperfect sensitivity 
observed in the serological tests used, we applied a 
correction of 85% to our multiple imputation estimates to 
obtain the IHR and to derive the proportion infected. We 
also considered test sensitivities of 80%, 90%, and 100% in 
sensitivity analyses.
To characterise uncertainty in seroprevalence estimates, 
1000 values were drawn from Student’s t distribution 
(the reference distribution for the multiple imputation 
inference), and 1000 values for the IHR were derived.
7934 patients from nursing homes had been admitted 
to hospital with SARS-CoV-2 infection by May 6, 2020, 
Research in context
Evidence before this study
To identify past analyses aiming to reconstruct in real time the 
number of infections from the joint analysis of serological and 
hospitalisation or death data, we searched PubMed 
for peer-reviewed articles published between Jan 1 
and Dec 10, 2020, using the search query (“COVID-19” OR 
“SARS-CoV-2”) AND “sero*” AND ((“hosp*” OR “death*”) AND 
(“rate*” or “number*”)), with no language restrictions. 
The query returned 372 results. Among those, eight were 
relevant to our study and provided estimates for the number of 
infections using a combination of serological and death data. 
None of these studies combined hospitalisation data and 
serosurveys to estimate the cumulative number of infections, 
nor were they designed to map infections in near real time and 
at different spatial scales in a country.
Added value of this study
Here, we provide a simple approach to monitor in near real time 
the number of infections at regional and national scales, using a 
method that combines age-stratified hospitalisation and 
seroprevalence data in France. We determined the number of 
infections in the different regions of metropolitan France 
between March 1, 2020, and Jan 15, 2021, and also estimated 
the proportion of cases detected by surveillance.
Implications of all the available evidence
Our findings show how hospitalisation data can inform on the 
proportion of infected population even if a nationwide 
serological study is unavailable. In the absence of contemporary 
serosurveys, our study shows that the proportion infected by 
SARS-CoV-2 might be higher than 20% in some French regions.
See Online for appendix
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but because the dynamics of transmission in that popu-
lation differ to those in the general population, and as 
they were not part of the cohort target population used 
for the estimation of the IHR, those patients were 
excluded from the calculation.
Reconstruction of the dynamics of infection
The curve of the daily number of infections was recon-
structed from the daily number of hospital admissions and 
the distribution of the delay from infection to hospitalisa-
tion. For each age group, the number of infections was 
obtained as the deconvolution of the daily number of 
hospitalisations and the infection-to-hospitalisa tion delay 
distribution, divided by the IHR (appendix p 1). The 
infection-to-hospitalisation delay is discrete and parameter-
ised with a gamma distribution with a mean of 11 days and 
SD of 3·2 days.12 The deconvolution approach used a 
Richardson-Lucy scheme that was adapted to account for 
right censoring in the hospitalisation curve (appendix 
pp 1, 4).13 The number of infections was reconstructed 
for all 13 regions of metropolitan France. Hospitalised 
individuals with missing age repre sented 0·7% (n=1480) 
of total hospital admissions and were not included in 
the study.
The heterogeneity of infections across regions was 
assessed using the coefficient of variation (CV). We 
report the estimated cumulative number of infections in 
the adult population on May 11, 2020 (after the first 
wave), on Oct 31, 2020 (during the second wave before 
the lockdown), and on Jan 15, 2021 (most recent estimate).
Internal and external validation of seroprevalence 
estimates
To internally validate our method, we compared sero-
prevalence estimates of the SAPRIS study in Grand Est, 
Ile-de-France and Nouvelle-Aquitaine with the sero-
prevalence predicted by our method on the median date of 
the study (May 14, 2020), reconstructed from the infections 
that happened up to April 25, to account for the 19-day 
delay between infection and seroconversion. 
We validated our method externally using a separate 
national seroprevalence study3 done between May 2 and 
June 2, 2020, among individuals aged 15 years or older in 
12 regions of metropolitan France. Serological results for 
SARS-CoV-2 were measured by the detection of IgG 
antibodies directed against the viral envelope using the 
ELISA-S method on 12 114 samples from throughout 
France. Corsica was excluded from this analysis since 
only 36 samples were available. We compared the results 
of this survey with the seroprevalence predicted by our 
method on May 17, 2020, the median date of sample 
collection, which we reconstructed from the predicted 
infections up to April 28 in those 12 regions (assuming a 
19-day delay between infection and seroconversion).
Pearson’s correlation was used to compare seropreva-
lence estimated with the model and from the external 
dataset.
Estimation of the proportion of infections detected by 
surveillance
Dates of infections of confirmed cases were recon-
structed with the same deconvolution approach using the 
national virological surveillance database of confirmed 
cases (SI-DEP; appendix p 1) and assuming the infection-
to-detection delay has a gamma distribution of mean 
8·5 days and SD 2·8 days, which accounts for an 
incubation period of 5·5 days14 and a delay of 3 days to 
testing.15 Proportions of infections detected by surveil-
lance were estimated over three periods (June 1 to 
Aug 31, 2020; Sept 1 to Oct 31, 2020; and Nov 1, 2020 to 
Jan 15, 2021) for all 13 regions as the ratio of the cumulative 
number of infections reconstructed from the confirmed 
cases recorded in SI-DEP over the cumula tive number of 
infections, as estimated with the hospitalisation data.
Sensitivity analyses
Several sensitivity analyses were done. We studied the 
impact of the delay distributions on the estimated 
Figure 1: Description of seroprevalence and hospitalisation data
(A) Estimates of seroprevalence by age group in the Île-de-France and Grand Est regions, in May to June, 2020 
(median date May 14). (B) Cumulative number of hospitalisations per 100 000 population, in Île-de-France and 
Grand Est, from March 1 to May 6, 2020. (C) Estimates of infection–hospitalisation ratio by age group in 
Île-de-France and Grand Est. The y-axis is displayed in logarithmic scale. (D) Daily number of hospitalisations by age 
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proportion of infected individuals in the population and on 
the proportion of cases detected (appendix p 2). We 
changed the mean and variance of the gamma distribution 
of the time-to-hospitalisation delay, and varied the delay 
with age and over the course of the epidemic (appendix 
pp 12–14). In another series of sensitivity analyses, we 
varied the distribution of infection-to-detection delays and 
changed the delays during the course of the epidemic 
(appendix pp 15–16). We also varied the cutoff date chosen 
for the estimation of the IHR (appendix p 17). Finally, we 
evaluated the impact of a 10–30% decrease of the IHR 
during the second wave.
R (version 3.6.1) was used for all statistical analyses. 
The latest estimates are available online.
Ethical approval
Ethical approval and written or electronic informed 
consent were obtained from each participant before 
enrolment in the original cohort. The SAPRIS survey was 
approved by the Institut National de la Santé et de la 
Recherche Médicale ethics committee (approval number 
20-672; March 30, 2020). The SAPRIS-SERO study was 
approved by the Sud-Mediterranée III ethics committee 
(approval number 20.04.22.74247) and electronic informed 
con sent was obtained from all participants for dried blood 
spot testing.
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
Observed seroprevalence in the Île-de-France and 
Grand Est regions in May to June, 2020, was highest 
among 40–49-year-olds (14·0%, 95% CI 11·6–16·7) and 
lower in older age groups, reaching a minimum among 
those aged 70 years or older (4·4%, 2·8–7·0; figure 1). 
Both the cumulative number of hospitalisations per 
100 000 population and the IHR increased with age, with 
Figure 2: Reconstruction of the proportion infected in metropolitan France
(A) Scatter plot of the seroprevalence in regions estimated with our model on May 11, 2020 (x-axis) and in seroprevalence studies in May, 2020 (y-axis), obtained 
from the SAPRIS serosurvey and EpiCov database. Data from the SAPRIS serosurvey in Île-de-France and Grand Est (triangles contoured in red) were used to calibrate 
the model. Bars represent the 95% CIs of the seroprevalence estimated by the model. (B) Proportion infected among adults in metropolitan France between 
March 1, 2020, and Jan 24, 2021. Timing of infection was reconstructed from the daily number of hospitalisations for COVID-19 and the delay from infection to 
hospital admission. The grey area represents the 95% CI. (C) Proportion infected in metropolitan France and in the 13 regions of metropolitan France, by date. 
(D) Geographical distribution of the proportion infected on Jan 15, 2021. (E) Proportion infected by age group and date. ARA=Auvergne-Rhône-Alpes. 
BFC=Bourgogne-Franche-Comté. BRE=Bretagne. COR=Corsica. CVL=Centre-Val de Loire. GES=Grand Est. HDF=Hauts-de-France. IDF=Île-de-France. 
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the IHR increasing from 0·4% (0·3–0·6) in 20–29-year-
olds to 17·6% (11·2–27·8) in 70–89-year-olds (figure 1). 
The patterns of hospitalisations by age and the IHR were 
similar in Grand Est and Île-de-France (appendix p 5).
Our model is calibrated to serological data collected in two 
regions in May, 2020, but can be used to reconstruct the 
seroprevalence and proportion infected in all regions and 
over time (figure 2). Consistent with national sero prevalence 
from the dataset for external validation,3 we estimated that 
4·8% (95% CI 4·3–5·4) of adults were seropositive to SARS-
CoV-2 in May, 2020, in metropolitan France. Our regional 
estimates of sero prevalence in May were strongly correlated 
with the external validation dataset (coefficient of correlation 
0·89), with ten of the 12 estimates contained in the 95% CI 
of the serosurvey (figure 2A). After correcting for the 
imperfect sensitivity of the serological assay, we found that 
5·7% (5·1–6·4) of the adult population had been infected by 
SARS-CoV-2 by May 11, 2020, in metropolitan France, with 
important regional variations (figure 2B, C). The proportion 
of the adult population that had been infected remained 
stable during the summer months in 2020 and increased in 
September to reach 14·9% (13·2–16·9) by Jan 15, 2021 
(appendix p 9). On that date, the proportion infected was 
highest in Île-de-France (ie, Paris area; 26·5%, 23·4–29·8), 
followed by Provence-Alpes-Côte d’Azur (19·7%, 17·2–22·4), 
Grand Est (18·2%, 16·1–20·6), Bourgogne-Franche-Comté 
(16·2%, 14·2–18·5), and Auvergne-Rhône-Alpes (15·7%, 
13·8–17·9; figure 2D; appendix p 9). The lowest proportion 
was in Brittany (5·1%, 4·5–5·8). The proportion infected 
was more homo geneous across regions in January, 2021 
(CV 0·50) than in May, 2020 (0·74).
The proportion infected in metropolitan France was 
highest in those aged 20–49 years (20·4%, 95% CI 
15·6–26·3), with lower rates of 9·7% (6·9–14·1) in those 
aged 50 years or older (figure 2E; appendix p 10). The 
same pattern by age was seen in most regions, with the 
risk of infection in those aged 20–49 years being 2–3 times 
higher than that in those aged 50 years or older, depending 
on the region (figure 3).
We estimated that 54·5% (95% CI 47·4–61·9) of SARS-
CoV-2 infections in the adult population were detected by 
surveillance between June, 2020, and January, 2021, with 
a probability of detection of 40·2% (34·3–46·3) in June 
to August, 2020; 62·3% (54·7–70·5) in September to 
October, 2020; and 49·3% (42·9–55·9) in November, 2020, 
to January, 2021 (figure 4; appendix p 11). The probability of 
detection between June, 2020, and January, 2021, was 
higher in those aged 50 years or older (68·7%, 54·4–82·6) 
than in those aged 20–49 years (47·1%, 39·4–55·1; figure 4). 
These estimates are consistent with a simple analysis of the 
raw data from the SI-VIC and SI-DEP databases: between 
June 1 and Nov 30, 2020, approxi mately 170 000 adults were 
hos pital ised and 2 400 000 cases were detected by surveil-
lance in metropolitan France, leading to a proportion detec-
ted of about 46% for an average estimated IHR of 3·3%.
In our baseline scenario, we assumed that the sensitivity 
of the serological test was 85%. In a sensitivity analysis, 
we found that estimates of the proportion infected by 
Jan 15, 2021, increased from 12·7% (95% CI 11·2–14·3) 
for a sensitivity of 100% to 15·8% (14·0–18·0) for a 
sensitivity of 80% (figure 5A). The proportion of infections 
that were detected varied from 51·2% (44·5–58·1) for 
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Figure 3: Proportion infected in the regions by age group and over time
(A) Estimates for the 13 regions of metropolitan France are shown on three dates. (B) Relative risk of infection of 
younger (<50 years) versus older (≥50 years) individuals. ARA=Auvergne-Rhône-Alpes. BFC=Bourgogne-Franche-
Comté. BRE=Bretagne. COR=Corsica. CVL=Centre-Val de Loire. GES=Grand Est. HDF=Hauts-de-France. 
IDF=Île-de-France. NAQ=Nouvelle-Aquitaine. NOR=Normandie. OCC=Occitanie. PAC=Provence-Alpes-Côte d’Azur. 
PDL=Pays de la Loire.
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In a simulation study, we checked that our deconvolution 
approach could correctly retrieve the daily numbers of 
infections if delay distributions (from infection to hos-
pitalisation and from infection to detection) were known 
(appendix pp 1, 4). However, this approach is in principle 
sensitive to uncertainty in these distributions. We therefore 
con ducted a series of sensitivity analyses and showed that 
our results on the proportion infected and proportion 
detected were robust to misspecification of the delay 
distributions (appendix pp 2, 12–16). This is because 
we were not aiming to precisely estimate the number of 
infections on a given day, but only the cumulative number 
of infections since the start of the pandemic. We also 
showed that our results are robust to changes in the cutoff 
date used to compute the IHR (May 6, 2020), because 
epidemic activity was low in France in May, 2020 
(appendix pp 2, 17).
In a sensitivity analysis, we found that a 10–30% 
reduction in the IHR during the second wave would have 
little impact on estimates of the proportion infected 
overall (15·8% [95% CI 13·9–17·9] for 10% reduction and 
18·4% [16·2–20·9] for 30% reduction; appendix p 6) but 
would reduce the proportion of infections being detected 
to 49·6% (43·2–56·4) for 10% reduction in the IHR and 
to 39·3% (34·3–44·7) for 30% reduction (appendix p 6).
Discussion
We have presented a method to reconstruct the proportion 
of the adult population infected by SARS-CoV-2 by region 
and age group from the joint analysis of readily available 
hospital surveillance data and existing serological surveys. 
This approach offers a simple way to track the number 
of infections in the population with a lag of a few weeks 
(ie, from infection to hospitalisation), which is challenging 
in the absence of regular, large-scale, representative 
serosurveys.
After accounting for the imperfect sensitivity of serology, 
we estimate that the proportion infected by SARS-CoV-2 in 
metropolitan France increased by two to three times from 
about 6% in May, 2020, to about 15% in mid-January, 2021. 
There are important differences between the two waves. 
First, the first wave occurred over a much shorter time 
period than the second wave that is still ongoing (figure 2). 
Second, while the first wave was mostly concentrated in 
two regions, all regions were impacted by the second wave. 
As a consequence, the proportion infected was more 
homogeneous in January, 2021, than in May, 2020. How-
ever, substantial heterogeneities remain. For example, 
the proportion infected in Île-de-France (Paris area) was 
about twice the national average. Overall, relatively similar 
patterns of infection by age were reconstructed in the 
different regions, with individuals aged 20-49 years being 
at substantially higher risk of infection.
Assuming that those infected are immunised against 
reinfection, the estimated 27% immunity could contribute 
to slowing down the spread of the virus in Île-de-France. 
Consider, for example, a situation in which control 
measures are such that, in a naive population, a case 
infects on average 1·6 people (reproduction number 
R0=1·6). In such a scenario, we would expect the number 
of cases to double about every 10 days. With 27% immunity, 
the effective reproduction number Reff would be reduced to 
0·73 × 1·6=1·2, leading to a substantially longer doubling 
time of about 26 days. However, given the very high 
transmissibility of SARS-CoV-2 (estimated at R0=3),12 about 
70% herd protection is likely to be needed for viral 
circulation to stop if all control measures were lifted.16 In 
the absence of control measures, 27% immunity would be 
insufficient to avoid a major crisis in hospitals since Reff 
would then be 0·73 × 3=2·32, with the number of cases 
expected to double about every 6 days. This does not take 
into account the potential waning of natural immunity.
For the period between June and August, 2020, we 
estimated that 40·2% (95% CI 34·3–46·3) of infections 
were detected, which is consistent with another modelling 
study15 that reported a detection rate of 38% (35–44) at the 
end of June. In our baseline scenario, we assumed a 
Figure 4: Proportion of infections detected by surveillance over different 
periods between June, 2020, and January, 2021
Bars represent 95% CIs.
Figure 5: Sensitivity analysis
(A) Proportion infected on Jan 15, 2021, assuming different sensitivities of the 
serological tests. (B) Proportion of infections detected by surveillance between 
June, 2020, and January, 2021, assuming different sensitivities of the serological 
tests. In our baseline analysis, we consider a sensitivity of the test of 85%.
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sensitivity of 85% for our assay, consistent with existing 
estimates.17 Higher sensitivities would lead to slightly 
lower estimates of the proportion infected and would 
inflate the proportion of infections being detected by 
surveillance at surprisingly high levels in some age groups.
Estimates of the proportion of the population infected 
by SARS-CoV-2 constitute useful contextual information 
to better characterise the burden of infection and 
epidemic dynamics in regions, as well as to ascertain the 
performance of surveillance. Such estimates are also 
important to ensure that mathematical models used to 
support policy making are correctly calibrated. However, 
it would be premature to use them as a basis to design 
differential control strategies in regions. First, although 
most people infected by SARS-CoV-2 appear to acquire 
protection against reinfection for at least 6 months,1,2 we 
still lack data to document waning of immunity over 
longer time periods. Immunity might also be less 
important for asymptomatic infections that constitute a 
substantial proportion of infections.18 If there is waning of 
immunity, in the absence of vaccines, the estimated 
number of people infected by SARS-CoV-2 will be an 
upper bound of the number of people that are protected 
against infection. The interpretation of contemporary 
seroprevalence estimates might be equally challenging 
since antibody decay following infection is not necessarily 
synonymous with a loss of protection.19 Therefore, in the 
long run, in the absence of vaccines, the proportion 
protected against SARS-CoV-2 could fall between the 
proportion seropositive estimated from seroprevalence 
studies and the proportion infected estimated with an 
approach such as ours. Obviously, as the vaccine roll-out 
progresses, it will be essential to track the level of 
immunity acquired through vaccination. Second, regions 
with the highest proportions of infected population might 
also be those that have larger transmission rates for 
example because of larger population densities. Third, we 
need to remain cautious in a context of emergence of new 
variants that are more transmissible and appear to partly 
escape the immune response.20 As more recent sero-
prevalence studies and data on the duration of immunity 
become available, this information could easily be 
integrated into our statistical framework to estimate the 
proportion of the population that is currently immunised 
from the time series of infections over time that we 
reconstructed and an assumption about the distribution 
of the duration of immunity.
Our estimates rely on the assumption that age-specific 
IHRs remained constant over time and across regions. 
However, it is possible that IHRs changed during the 
course of the pandemic—eg, as a function of the stress on 
the health-care system. In a sensitivity analysis, assuming 
a reduced IHR during the second wave had little impact 
on the proportion infected. Our IHR estimates are 
calculated during the first pandemic wave and therefore 
constitute averages over a time period during which the 
stress on the health-care system changed rapidly. They are 
nonetheless in line with national estimates of the IHR for 
other countries.21 IHRs might also vary with regional 
hospitalisation policies. For example, if there is higher 
propensity to hospitalise young adults in some regions, 
we might overestimate the proportion of infected 
individuals in this age group and therefore in the overall 
population. However, despite these possible regional and 
contextual variations in IHRs, our regional estimates of 
sero prevalence were strongly correlated with our external 
validation dataset, despite using IHR estimates only for 
Île-de-France and Grand Est, the two regions that were the 
most affected during the first wave. IHRs might also have 
changed if the population of those infected changed 
between the first and second wave. Our results should be 
robust to variations in the age distribution of those 
infected since our approach controls for age. However, if 
in a given age group, the proportion of infected individuals 
with higher IHR (eg, because of comorbidities) decreased 
between the first and second wave owing to improved 
protective measures, we might underestimate the propor-
tion infected in that age group. Patients with undiagnosed 
COVID-19 admitted to hospital at the very beginning of 
the pandemic might have led to over estimation of the 
IHR. However, any such effect would probably be small 
since most COVID-19-related hos pitalisa tions are likely to 
have been detected once hospital surveillance was in place 
from mid-March, 2020, given the exponential nature of 
the first wave. Since our framework relies on the analysis 
of hospitalisation data and very few children were 
hospitalised, our approach would be likely to generate 
large CIs for that age group. We therefore decided to focus 
on adults.
In conclusion, we have presented a simple framework 
to track the proportion of the population infected with a 
lag of a few weeks using the joint analysis of age-stratified 
hospitalisation and serological data. Age-specific IHRs 
might vary by country given the different health-care 
systems. However, it should be easy to recalibrate our 
model to data from countries in which hospital sur-
veillance and results of serosurveys are available.
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